The PennZone

  • Home
  • Books
  • Entertainment
  • Marketing
  • Non-profit
  • Music
  • Education
  • Legal
  • Business

Large Study Analyzes Two Different Classes of ADHD Drugs in Preschool-Age Children
The PennZone/10124083

Trending...
  • Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
  • Congressman Chuck Edwards (NC-11) Presents ReadyCommunities Partnership 2026 National Service Award to Local Businessman / US Air Force Veteran
  • Garage door installation or repair in Minnesota? Which makes more sense for your family?
PHILADELPHIA, May 4, 2021 /PRNewswire/ -- In a multi-institutional study, researchers in the Developmental-Behavioral Pediatrics Research Network (DBPNet), led by Children's Hospital of Philadelphia (CHOP), have conducted the first and largest analysis to date comparing the effectiveness and side effects of stimulants like methylphenidate (Ritalin) and alpha-adrenergic agonists like guanfacine (Tenex) in preschool-age children. The researchers found that both classes of drugs have benefits, with differing side effects, suggesting that decisions on which class of drugs to prescribe should be made based on individual patient factors. The retrospective study was published today in JAMA.

"This is really the first study of any size to report on the frequency of improvement and side effects of drugs like guanfacine in preschool-age children," said senior author Nathan J. Blum, MD, Chief of the Division of Developmental and Behavioral Pediatrics at CHOP. "While this study confirms that clinicians are using drugs like guanfacine in preschoolers and that those drugs may be useful in some children, the research also strongly suggests we need future research to look in a rigorous way at the use of alpha-adrenergic agonists in this age group."

More on The PennZone
  • Put Your Herd on Your Phone: Kiko Nation Makes Livestock Management Simple
  • Future Intelligence Think Tank Surpasses 1,000 Members Exploring Human and Artificial Intelligence
  • Gary Bernstein Expands Media Leadership Role With Senior Strategic Advisor Appointment To Blacksun Private Equity
  • Headline: House of Nova Paints Every Face in Gold at New York Fashion Week
  • Can Government Operate Better Through Innovation?

To assess the use, effectiveness, and side effects of stimulants and alpha-adrenergic agonists in preschoolers, the researchers reviewed electronic health records of 497 children seen at seven DBPNet outpatient developmental-behavioral pediatric practices between January 2013 and July 2017. Children included in the study were under the age of 6 when first treated with an alpha-adrenergic agonist or stimulant.

The researchers found that 175 children (35%) were prescribed an alpha-adrenergic agonist like guanfacine, while 322 children (65%) were prescribed a stimulant like methylphenidate (Ritalin). Although both groups reported improvement in symptoms, the benefit was slightly larger among those prescribed stimulants (78% vs. 66%).

However, in terms of side effects, patients taking alpha-adrenergic agonists reported fewer side effects than those taking stimulants, with lower rates of moodiness/irritability (50% vs. 29%), appetite suppression (38% vs. 7%), and difficulty sleeping (21% vs. 11%). The only side effect that was more common for those taking alpha-adrenergic agonists than those taking stimulants was daytime sleepiness (38% vs. 3%).

The researchers also found children younger than 4 years old who were prescribed a drug like guanfacine were likely to continue using the medication for longer than if they were prescribed a stimulant. In contrast, children aged 5 to younger than 6 prescribed were likely to continue using the medication for longer if they were prescribed a stimulant. For those ages 4 to 5, there was no significant difference between medications.

"Although the retrospective nature of our study means we weren't able to tell why patients stopped a given medication rather than continued with it, these data support potentially tailoring medication based on a child's age, among other personal factors that might influence medication decisions," Blum said. "Future research should seek to learn more about the use of these classes of drugs in preschool-age children so that we can prescribe the most effective therapy for each patient."

More on The PennZone
  • Michael H. Kaplan Advocates for Seriously Injured Colorado Workers Who Need In-Home Care
  • Her Song Lives On: Remembering Mrs. Darlene Davis Porter
  • Infinity Infusion Solutions Named Finalist for D Magazine's D CEO 2026 Excellence in Healthcare Awards
  • Pittsburgh Creators Launch Clever New Children's Book, "The Sock Sleuth!"
  • Canadian Tint Expo 2027: Why Every Window Tinter Should Compete in Niagara Falls on April 3rd & 4th

Other institutions involved in the study include Boston Children's Hospital; the Perelman School of Medicine at University of Pennsylvania; University of Oklahoma Health Sciences Center; Keck School of Medicine at University of Southern California, Los Angeles; Children's Hospital Los Angeles; Children's Hospital Colorado; Medical University of South Carolina; Stanford University; and Atrium Health.

Harstad et al. "α2-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder," JAMA, online May 4, 2021, DOI: 10.1001/jama.2021.6118

About Children's Hospital of Philadelphia: Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. In addition, its unique family-centered care and public service programs have brought the 595-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu

Contact: Camillia Travia
Children's Hospital of Philadelphia
(425) 492-5007
[email protected]

SOURCE Children's Hospital of Philadelphia

Related Links

http://www.chop.edu
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Houston This October
  • The Social Capital Revolution Comes to Phoenix!
  • Lawsuit Alleges American Deli Food Caused Severe Illness, Acute Kidney Failure, And Eight-day Hospitalization
  • FBI/DoW plot uncovered to hurt Trump/Vance through encouraged "widespread" cybersecurity breaches and racketeering theft of $80m in USDA payments
  • Bettingbladet releases H1 2026 report on the Swedish online gambling market
  • Garage door installation or repair in Minnesota? Which makes more sense for your family?
  • SMACK Fight Week Takes Over Philadelphia
  • Super Rooter Expands to 190 Plumbing, Sewer, and Drain Service Locations Across the United States
  • European Patent for ALS Program Expands the Story: HOPE Deploys Robotic TMS & FDA Commercialization Path Advances: NRx Pharmaceuticals: NAS DAQ: NRXP
  • VICTURY Sports Announces Formation of Youth Sports League Built on the Official, Patented, and Award-Winning Keepy Uppy® Ball
  • Spearmint Publishes Full Design of Its Mining Pool Before Building It, Including Legal Drafts
  • Congressman Chuck Edwards (NC-11) Presents ReadyCommunities Partnership 2026 National Service Award to Local Businessman / US Air Force Veteran
  • Cress Creeks Farm Opens Fall Corn Maze and Baby Lamb Hayride Experience in Ellijay, Georgia
  • Brewtay Coffee Introduces Specialty Instant Line Designed for High-Velocity Commuters and Travelers
  • Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
  • Ten Ten Ten Awards Provisional Certification to Cara AI for Home-Based Health Assessments
  • IDI Consulting Partners with the American Heart Association to Advance Heart Health Awareness
  • Kerri Lawless Introduces New Home-Selling Option for Local Homeowners
  • Bethany Nikitenko Appointed to Philadelphia Trial Lawyers Association Diversity Committee
  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)

Popular on PennZone

  • Benny Turner Revisits Freddie King's Legacy for 50th Anniversary of His Passing - 221
  • Easwe Lightweight Electric Wheelchair Collection with Travel-Focused Mobility Solutions - 196
  • Church Tradition Takes an Unexpected Turn at the Ford Community & Performing Arts Center - 189
  • Master Of Science, Juggernaut Of The Screen: Landon Brittain Emerges As Hollywood's Most Unlikely Leading Man - 182
  • 3ptechies Partners with Coolmuster to Give Away Data Recovery Software Licenses - 174
  • Black Dog Venture Partners and VC Fast Pitch to Host "San Francisco Investors and Innovators" Networking Event - 154
  • FindCostSeg Launches Nationwide Directory for Cost Segregation Providers - 147
  • GitKraken Names Jim Shaw CEO as Software Teams Move From AI Adoption to Multi-Agent Orchestration - 144
  • INAD Warriors' 4th Annual "Dancing with the INAD Stars" Gala - 141
  • Michael Fischer, President and CEO of Client 1st Financial, Named to LVB 300 - 120

Similar on PennZone

  • Ragin' Cajun Announces New Cheeseburger Seasoning on National Cheeseburger Day
  • Warrant Activity, AVERSA™ Progress and a Potentially Transformative Fall Take Center Stage: Nutriband Inc. (N A S D A Q: NTRB)
  • Future Intelligence Think Tank Surpasses 1,000 Members Exploring Human and Artificial Intelligence
  • Gary Bernstein Expands Media Leadership Role With Senior Strategic Advisor Appointment To Blacksun Private Equity
  • Can Government Operate Better Through Innovation?
  • Infinity Infusion Solutions Named Finalist for D Magazine's D CEO 2026 Excellence in Healthcare Awards
  • Building a Diversified Healthcare Platform as Exosome Science, Telehealth, Diagnostics & Strategic Acquisitions Converge: NexTel Medical (OTCID: MAJI)
  • Retell AI White Label Platform for Agencies Launched by VoiceAIWrapper, With Branded Client Portals and No Per-Minute Markup
  • Notaron Expands Online Notarization Access Following Wisconsin Approval
  • Wings Air Helicopters Selected to Support VIP Transportation for Resorts World in New York
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us